The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a new evaluation tool.

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...

The risk calculator shows improved precision in a population larger than the original dataset used to validate the tool.

Bristol-Myers Squibb is getting the corporate equivalent of a polite shrug from analysts, with most advising investors to ...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are ...

Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may ...

The president claimed his “most-favored nation” proposal would reduce some pharmaceutical prices by as much as 80%, but the ...

The third cycle of the drug price negotiations will involve drugs under Medicare Part B. New prices are set to take effect in ...

Bristol Myers Squibb (BMY) and MPLX present compelling value picks, offering high-income potential and attractive valuations ...

Older patients with Crohn’s disease are at elevated risk for recurrence following ileocolic resection but less frequently ...